NEW YORK, Feb. 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FXCM Inc. (“FXCM” or the “Company”) (NASDAQ:FXCM) and certain of its officers, on behalf of a class who purchased FXCM securities between March 15, 2012 and February 6, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fxcm.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) between September 4, 2009 through at least 2014, FXCM’s U.S. subsidiary were engaged in false and misleading solicitations of its retail foreign exchange customers by hiding its relationship with its most important market maker and by misrepresenting that its “No Dealing Desk” platform had no conflicts of interest with its customers; (2) FXCM’s U.S. subsidiary made false statements to the National Futures Association about its relationship with the market maker; and (3) consequently, Defendants’ statements regarding FXCM’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On February 6, 2017, the Commodities Futures Trading Commission (“CFTC”) found that FXCM was engaged in false and misleading solicitations of its retail foreign exchange customers by hiding its relationship with FXCM’s most important market maker and the fact that the Company’s “No Dealing Desk” platform had conflicts of interest with FXCM’s customers. Due to the above, CFTC barred FXCM from operating in the United States. Following this news, FXCM stock dropped $3.40 per share, or 50%, to close at $3.45 on February 7, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/fxcm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in FXCM you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bill Ackman Eyes New Fund to Bet Against Market Complacency
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



